![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
University Hospital, Basel, Switzerland |
---|---|
Information provided by: | University Hospital, Basel, Switzerland |
ClinicalTrials.gov Identifier: | NCT00861536 |
An open, multicenter, randomised, parallel group pilot study to investigate two different polyclonal rabbit immunoglobulin preparations for safety and efficacy: A comparison of ATG-Fresenius S to Thymoglobulin in prophylaxis for immunological high risk patients following renal transplantation. This non-inferiority trial shall demonstrate that ATG-Fresenius S is as efficacious as Thymoglobulin but has a better tolerance and fewer side effects.
Condition | Intervention | Phase |
---|---|---|
Transplantation, Kidney |
Drug: ATG Fresenius Drug: Thymoglobuline Genzyme |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | An Open, Multicenter, Randomised, Parallel Group Pilot Study to Investigate Two Different Polyclonal Rabbit Immunoglobulin Preparations for Safety and Efficacy:A Comparison of ATG-Fresenius S to Thymoglobulin in Prophylaxis for Immunological High Risk Patients Following Renal Transplantation |
Estimated Enrollment: | 40 |
Study Start Date: | January 2009 |
Estimated Study Completion Date: | January 2013 |
Estimated Primary Completion Date: | January 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
ATG: Experimental |
Drug: ATG Fresenius
Day 0: 9 mg/kg bw bolus Days 1-4: 3 mg/kg bw/d
|
Thymoglobuline: Active Comparator |
Drug: Thymoglobuline Genzyme
Day 0-3: 1.5 mg/kg bw/d
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Recipients, who are at least 18 years or older and have a high immunological risk defined by:
The presence of at least one donor-specific antibody (class I and/or II) detected and specified by flow-technology (FlowPRA and single antigen beads), which are
Exclusion Criteria:
Contact: Juerg Steiger, Prof | +41 61 265 44 04 | jsteiger@uhbs.ch |
Switzerland | |
University Hospital Basel, Transplantation Immunology and Nephrology | Recruiting |
Basel, Switzerland, 4031 | |
Contact: Juerg Steiger, Prof +41 61 265 44 04 jsteiger@uhbs.ch | |
Principal Investigator: Juerg Steiger, Prof |
Principal Investigator: | Juerg Steiger, Prof | University Hospital Basel, Transplantation Immunology and Nephrology |
Responsible Party: | University Hospital Basel ( Prof. Juerg Steiger ) |
Study ID Numbers: | 82/06 |
Study First Received: | March 12, 2009 |
Last Updated: | March 12, 2009 |
ClinicalTrials.gov Identifier: | NCT00861536 History of Changes |
Health Authority: | Switzerland: Swissmedic |
risk factors immunology |
Antibodies Immunoglobulins |